New Rochelle, NY, July 23, 2015--Rapid, large-scale screening to characterize the different subpopulations of multipotent cells that can be derived from fat tissue is an effective strategy to identify and select for specific cell types that would be advantageous for particular therapeutic applications in regenerative medicine and tissue engineering. The use of flow cytometry to determine the expression of a defined set of markers on the surface of human adipose-derived stromal cells (hASCs) is described in an article in Tissue Engineering, Part A, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Tissue Engineering website until August 23, 2015.
Michael Longaker, MD, MBA and coauthors, Stanford University School of Medicine (California), developed a comprehensive surface marker profile of undifferentiated (hASCs) using flow cytometry. They compared this to surface marker profiles for hASCs that have undergone differentiation to bone (osteogenic) or fat (adipogenic) cell lineages. The researchers describe these studies and identify which surface markers increase or decrease with osteogenic and adipogenic differentiation in the article "High-Throughput Screening of Surface Marker Expression on Undifferentiated and Differentiated Human Adipose-Derived Stromal Cells."
"Flow cytometry is a well established tool for the separation of cells on the basis of their size and surface markers," says Peter C. Johnson, MD, Vice President, Research and Development and Medical Affairs, Vancive Medical Technologies and President and CEO, Scintellix, LLC, Raleigh, NC. "This marriage of flow cytometry with the identification of regenerative cell subpopulations will likely prove to be very useful to a broad range of researchers in the field."
Research reported in this publication was supported by the National Institutes of Health under Award Number U01 HL099776 and the National Institute of General Medical Sciences under the training grant GM0736. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
Tissue Engineering is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published bimonthly, and Part C: Methods, published 12 times per year. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Vice President, Research and Development and Medical Affairs, Vancive Medical Technologies, an Avery Dennison business, and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed online at the Tissue Engineering website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy, and Advances in Wound Care. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.